India to Brazil: Gefitinib Export Trade Route

The India to Brazil Gefitinib corridor is one of India's established pharmaceutical export routes, with 19 shipments documented worth a combined $2.8M USD. The route is dominated by NATCO PHARMA LIMITED, which alone accounts for roughly 51% of all export value, reflecting the consolidated nature of India's gefitinib manufacturing sector.

Across 6 active suppliers, the average shipment value stands at $148.5K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (69%) and air (18%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.

Shipment activity peaks during July–September, with an average transit time of 29 days port-to-port. The route has recorded an annual growth rate of 29.4%, placing it at rank #8 among India's top gefitinib export destinations globally.

On the import side, key buyers of Indian gefitinib in Brazil include CIPLA BRASIL IMPORTADORA E, NATCOFARMA DO BRASIL LTDA, NATCOFARMA DO BRASIL LTDA, and 6 others. CIPLA BRASIL IMPORTADORA E is the single largest importer with 7 shipments valued at $1.2M USD.

India's gefitinib exports to Brazil are driven primarily by a handful of large-scale manufacturers. NATCO PHARMA LIMITED with 5 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 6 active exporters signals a competitive but concentrated market — buyers in Brazil benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — NATCO PHARMA LIMITED, CIPLA LIMITED, CIPLA LIMITED — together account for 100% of total trade value on this route. The average shipment value of $148.5K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as gefitinib 250mg tablets 30's 3760x30'sappendix 4r, rodtep entry no:10112other ref :ci no:123157 and gefitinib 250mg tablets 30 s 2670x30 s appendix 4r rodtepentry no 10112 ci no 122300, suggesting that buyers in Brazil tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, CIPLA BRASIL IMPORTADORA E is the largest importer with 7 shipments worth $1.2M USD — representing 43% of all gefitinib imports from India on this route. A total of 9 buyers are active on this corridor.